Abstract
Major depressive disorder (MDD) is associated with increased healthcare resources utilization, reduced quality-of-life, and substantial indirect costs. In the Kingdom of Saudi Arabia (KSA), there is a paucity of national-level data for MDD prevalence. A study reported a prevalence rate of 12% in the south-eastern region of the KSA. Vortioxetine and Sertraline have shown promising clinical results in MDD patients. However, these drugs are not yet included in the Ministry of Health (MoH) formulary of the KSA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
